


**REMARKS****I. Amendments to the Specification.**

In response to the Examiner's telephone inquiry dated May 17, 2006 regarding the relationship of the priority claim please consider the following. In the specification, paragraph [0001] has been amended to cancel reference to priority from U.S. provisional application No. 60/366,784, filed March 22, 2003 and to provide the continuation-in-part priority relationship to U.S. patent application Ser. No. 10/392,833.

The Examiner is invited to telephone the undersigned should any issues remain after the consideration of this response. Please charge any additional fees or credit any overpayments that may be required to Deposit Account No. 19-1025.

Respectfully requested,

May 17, 2006  
Date



R. Steve Thomas  
Registration No. 52,284  
Corporate Counsel  
Pfizer, Inc.  
575 Maryville Centre Drive MC5  
St. Louis, MO 63141  
Tel: 314-274-4908  
Fax: 314-274-5452